<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766310</url>
  </required_header>
  <id_info>
    <org_study_id>Folic-01</org_study_id>
    <nct_id>NCT01766310</nct_id>
  </id_info>
  <brief_title>Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children</brief_title>
  <official_title>Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children: a Randomized Double Blinded Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Sirikit National Institute of Child Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Sirikit National Institute of Child Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study was to determine whether folic acid supplementation could
      reduce plasma homocysteine in obese children and to determine the association between dietary
      folate, serum folate and homocysteine level through the randomized double blinded placebo
      controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis is common &amp; remains a significant clinical problem because of leading to
      myocardial infarction, stroke and cardiovascular death. Many studies founded
      hyperhomocysteinemia is an independent risk factor for those cardiovascular diseases which
      take responsible for about 10% of total cardiovascular disease risk. Reduction of elevated
      plasma homocysteine may prevent up to 25% of cardiovascular events. One of modifiable cause
      of hyperhomocysteinemia is prevention of vitamin deficiency, especially folate deficiency.

      Obese Thai children are probable risk for folate deficiency due to low dietary folate intake
      and low serum folate level from unbalanced diet (low vegetables intake &amp; high fat diet) and
      high prevalence of thalassemia. Moreover obese children are also at risk of atherosclerosis.
      However, no data have been reported about effect of folic acid supplementation on
      homocysteine level in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Homocysteine Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean difference of changes of homocysteine level between 2 treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Folate Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>correlation between serum folate and plasma homocysteine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Vitamin B12 Level</measure>
    <time_frame>8 weeks</time_frame>
    <description>correlation between serum vitamin B12 and plasma homocysteine level</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prevalence of Hyperhomocysteinemia</measure>
    <time_frame>8 weeks</time_frame>
    <description>prevalence of hyperhomocysteinemia in Thai obese children</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hyperhomocysteinemia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>folic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand</description>
    <arm_group_label>folic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sugar tablet manufactured to mimic folic acid tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age between 9-18 years

          -  Diagnosed obesity (BMI more than median plus two of standard deviation for age and sex
             according to WHO reference 2007)

        Exclusion Criteria:

          -  Secondary obesity

          -  Thalassemia disease

          -  Renal and hepatic dysfunction

          -  Drugs: anticonvulsant, estrogen, thiazides, metformin, cholestyramine, methotrexate,
             fibrates, nicotinic acid

          -  Previous vitamin supplementation 1 month before study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orawan Iamopas, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Sirikit National Institute of Child Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatrics, Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Sirikit National Institute of Child Health</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Solini A, Santini E, Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obes (Lond). 2006 Aug;30(8):1197-202. Epub 2006 Feb 21.</citation>
    <PMID>16491109</PMID>
  </reference>
  <reference>
    <citation>Papandreou D, Malindretos P, Arvanitidou M, Makedou A, Rousso I. Oral supplementation of folic acid for two months reduces total serum homocysteine levels in hyperhomocysteinemic Greek children. Hippokratia. 2010 Apr;14(2):105-8.</citation>
    <PMID>20596265</PMID>
  </reference>
  <reference>
    <citation>Papandreou D, Malindretos P, Arvanitidou M, Makedou A, Rousso I. Homocysteine lowering with folic acid supplements in children: effects on blood pressure. Int J Food Sci Nutr. 2010 Feb;61(1):11-7. doi: 10.3109/09637480903286371.</citation>
    <PMID>19939196</PMID>
  </reference>
  <reference>
    <citation>Pe√±a AS, Wiltshire E, Gent R, Hirte C, Couper J. Folic acid improves endothelial function in children and adolescents with type 1 diabetes. J Pediatr. 2004 Apr;144(4):500-4.</citation>
    <PMID>15069400</PMID>
  </reference>
  <reference>
    <citation>Gargari BP, Aghamohammadi V, Aliasgharzadeh A. Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes. Diabetes Res Clin Pract. 2011 Oct;94(1):33-8. doi: 10.1016/j.diabres.2011.07.003. Epub 2011 Jul 28.</citation>
    <PMID>21802161</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <results_first_submitted>August 10, 2014</results_first_submitted>
  <results_first_submitted_qc>October 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2015</results_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Sirikit National Institute of Child Health</investigator_affiliation>
    <investigator_full_name>Pavinee Intakorn</investigator_full_name>
    <investigator_title>Queen Sirikit National Institute of Child Health</investigator_title>
  </responsible_party>
  <keyword>Folic acid</keyword>
  <keyword>Folate</keyword>
  <keyword>Homocysteine</keyword>
  <keyword>Obese</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhomocysteinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
placebo: sugar tablet manufactured to mimic folic acid tablet</description>
        </group>
        <group group_id="P2">
          <title>Folic Acid</title>
          <description>Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
Folic Acid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mean and SD</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
placebo: sugar tablet manufactured to mimic folic acid tablet</description>
        </group>
        <group group_id="B2">
          <title>Folic Acid</title>
          <description>Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
Folic Acid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.73" spread="1.64"/>
                    <measurement group_id="B2" value="11.08" spread="1.57"/>
                    <measurement group_id="B3" value="10.90" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes of Homocysteine Level</title>
        <description>Mean difference of changes of homocysteine level between 2 treatment groups</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
placebo: sugar tablet manufactured to mimic folic acid tablet</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
Folic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Homocysteine Level</title>
          <description>Mean difference of changes of homocysteine level between 2 treatment groups</description>
          <units>¬µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="1.25"/>
                    <measurement group_id="O2" value="-1.35" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.68</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>1.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Folate Level</title>
        <description>correlation between serum folate and plasma homocysteine level</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Vitamin B12 Level</title>
        <description>correlation between serum vitamin B12 and plasma homocysteine level</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Prevalence of Hyperhomocysteinemia</title>
        <description>prevalence of hyperhomocysteinemia in Thai obese children</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
placebo: sugar tablet manufactured to mimic folic acid tablet</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
Folic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Hyperhomocysteinemia</title>
          <description>prevalence of hyperhomocysteinemia in Thai obese children</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
placebo: sugar tablet manufactured to mimic folic acid tablet</description>
        </group>
        <group group_id="E2">
          <title>Folic Acid</title>
          <description>Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
Folic Acid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Orawan Iamopas</name_or_title>
      <organization>Queen Sirikit National Institute of Child Health</organization>
      <phone>66-2-354-8415 ext 3327</phone>
      <email>orawaneamopas@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

